e-learning
resources
Munich 2014
Sunday, 07.09.2014
Pulmonary hypertension: pathobiology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Nebivolol and pulmonary hypertension
F. Perros, S. Bentebbal, B. Ranchoux, P. Dorfmüller, F. Lecerf, E. Fadel, G. Simonneau, M. Humbert, H. J. Bogaard, S. Eddahibi (Le Kremlin-Bicetre, Le Plessis-Robinson, France; Amsterdam, Netherlands)
Source:
International Congress 2014 – Pulmonary hypertension: pathobiology
Session:
Pulmonary hypertension: pathobiology
Session type:
Poster Discussion
Number:
317
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Perros, S. Bentebbal, B. Ranchoux, P. Dorfmüller, F. Lecerf, E. Fadel, G. Simonneau, M. Humbert, H. J. Bogaard, S. Eddahibi (Le Kremlin-Bicetre, Le Plessis-Robinson, France; Amsterdam, Netherlands). Nebivolol and pulmonary hypertension. Eur Respir J 2014; 44: Suppl. 58, 317
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Endothelial-to-mesenchymal transition in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Immune signatures in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Pulmonary arterial hypertension – A single-centre experience
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Long-term screening for pulmonary hypertension after pulmonary embolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Female pulmonary arterial hypertension is associated with decreased microRNA96 expression
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Prognosis factors of recurrent pulmonary thromboembolism
Source: International Congress 2014 – Acute pulmonary embolism
Year: 2014
Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Th17 inflammation and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Non-invasive cardiac output assessment in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Characteristics of patients with pulmonary hypertension in end stage renal disease
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Cerebral oxygenation in highlanders with high altitude pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange
Year: 2014
Molecular study of genetic modifiers in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Long-term data from the Swiss pulmonary hypertension registry
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Would RDW be a prognostic factor in pulmonary arterial hypertension?
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Exercise-induced pulmonary pressure changes in scleroderma patients – A follow-up study
Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept